Tag: SGLT2 inhibitors
-
DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation
New Findings Question SGLT2 Inhibitors for Post-Ablation AF Recurrence In a development that surprises many in the cardiology community, the DARE-HF trial examined whether the SGLT2 inhibitor dapagliflozin could reduce the burden of atrial fibrillation (AF) after catheter ablation. Conducted in patients who recently underwent ablation for AF, the study aimed to determine if adding…
-
DARE-AF Trial: Dapagliflozin Fails to Reduce AF Burden After Ablation
Overview: Aiming to Lower AF Recurrence With SGLT2 Inhibition The DARE-HF trial, conducted in New Orleans, tested whether dapagliflozin, an SGLT2 inhibitor, could reduce the burden of atrial fibrillation (AF) after catheter ablation. AF remains a leading heart rhythm disorder, and recurrence after ablation poses a persistent challenge for patients and clinicians. While SGLT2 inhibitors…
-
Knowledge Domain and Emerging Trends on Dapagliflozin for Heart Failure: A Bibliometric Analysis (2012–2024)
Introduction Dapagliflozin, a leading SGLT2 inhibitor, has evolved from a glucose-lowering agent to a cornerstone therapy for heart failure (HF). Built on pivotal trials like DAPA-HF and DELIVER, dapagliflozin now targets a broad spectrum of HF patients, including those without diabetes. A recent bibliometric analysis of literature from 2012 to 2024 maps the global research…
-
Knowledge Domain and Emerging Trends on Dapagliflozin for Heart Failure: A Bibliometric View (2012–2024)
Introduction: Dapagliflozin as a Cornerstone in Heart Failure Therapy Heart failure (HF) remains a global healthcare challenge with rising prevalence and substantial economic burden. Dapagliflozin, an SGLT2 inhibitor, emerged as a pivotal therapy beyond glucose control, driven by landmark trials such as DAPA-HF. A bibliometric analysis of research from 2012 to 2024 reveals how scientific…
-
Knowledge Gaps and Emerging Trends in Dapagliflozin for Heart Failure: A 2012–2024 Bibliometric Analysis
Introduction Dapagliflozin, a pioneering SGLT2 inhibitor, has evolved from a diabetes medication to a cornerstone therapy for heart failure (HF). Built on pivotal trials such as DAPA-HF and DELIVER, its role now spans reduced and preserved ejection fraction HF subtypes, with ongoing investigations into cardiorenal protection and fibrosis modulation. This article interprets a comprehensive bibliometric…
-
New Horizons in Heart Failure Treatment: Clinician Education
Introduction: A new ACC program to elevate heart failure care The American College of Cardiology (ACC) is launching Transformation of HF Care: New Horizons in Treatment, an 18-month education program designed to equip clinicians with the latest advances in heart failure (HF) management. The initiative seeks to bridge gaps between evolving research and everyday practice,…
-
New ACC Program Aims to Educate Clinicians on the Latest Advances in Heart Failure Treatment
Overview: Transforming Heart Failure Care Heart failure (HF) remains a leading cause of hospitalization and a significant public health challenge, with more than 6 million Americans affected. The American College of Cardiology (ACC) has launched a new educational initiative, Transformation of HF Care: New Horizons in Treatment, designed to equip clinicians with the latest advances…
-
Transformation of Heart Failure Care: New Horizons in Treatment for Clinicians
Introduction: A New Educational Era in Heart Failure Care The American College of Cardiology (ACC) is launching Transformation of HF Care: New Horizons in Treatment, an 18-month program designed to equip clinicians with the latest advances in heart failure (HF) management. As the disease remains a leading cause of hospitalization and increasingly affects diverse populations,…